{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:20:32Z","timestamp":1791433232508,"version":"4.3.3"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","award":["K\/ZDS\/002936"],"award-info":[{"award-number":["K\/ZDS\/002936"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015077","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum Wydzia\u0142 Lekarski","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vph.2022.106977","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T11:50:47Z","timestamp":1646913047000},"page":"106977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein"],"prefix":"10.1016","volume":"144","author":[{"given":"Jakub","family":"Siudut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Z\u0105bczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Wo\u0142kow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Jawie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2022.106977_bb0005","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the global burden of disease study 2015","volume":"388","author":"Wang","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.vph.2022.106977_bb0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0025-6196(11)60544-2","article-title":"Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease","volume":"84","author":"Karalis","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.vph.2022.106977_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00000441-199401000-00003","article-title":"Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease","volume":"307","author":"Greilich","year":"1994","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.vph.2022.106977_bb0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.thromres.2018.12.020","article-title":"Sex difference in fibrin clot lysability: association with coronary plaque composition","volume":"174","author":"Ramanathan","year":"2019","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2022.106977_bb0025","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/01.ATV.0000241589.52950.4c","article-title":"Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis","volume":"26","author":"Collet","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2022.106977_bb0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0021-9150(98)00144-0","article-title":"Effects of lipids and lipoproteins on thrombosis and rheology","volume":"140","author":"Rosenson","year":"1998","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.vph.2022.106977_bb0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.atherosclerosis.2004.01.026","article-title":"Interrelationships between the fibrinolytic system and lipoproteins in the pathogenesis of coronary atherosclerosis","volume":"174","author":"Jovin","year":"2004","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.vph.2022.106977_bb0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/09537104.2011.596957","article-title":"Clot lysis time in platelet-rich plasma: method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid","volume":"23","author":"Panes","year":"2012","journal-title":"Platelets."},{"key":"10.1016\/j.vph.2022.106977_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-0039-1698460","article-title":"Interpretation and validation of maximum absorbance data obtained from turbidimetry analysis of plasma clots","volume":"120","author":"Pieters","year":"2020","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2022.106977_bb0050","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2352-3026(16)30184-3","article-title":"Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis","volume":"4","author":"Kunutsor","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.vph.2022.106977_bb0055","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/eurheartj\/ehx107","article-title":"Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies","volume":"38","author":"Kunutsor","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2022.106977_bb0060","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1538-7836.2006.01882.x","article-title":"Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease","volume":"4","author":"Undas","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2022.106977_bb0065","doi-asserted-by":"crossref","first-page":"354","DOI":"10.20452\/pamw.707","article-title":"Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol\/l","volume":"119","author":"Undas","year":"2009","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.vph.2022.106977_bb0070","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.thromres.2015.02.005","article-title":"Shotgun analysis of plasma fibrin clot-bound proteins in patients with acute myocardial infarction","volume":"135","author":"Suski","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2022.106977_bb0075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12014-017-9173-x","article-title":"Optimization of quantitative proteomic analysis of clots generated from plasma of patients with venous thromboembolism","volume":"14","author":"Stachowicz","year":"2017","journal-title":"Clin. Proteomics"},{"issue":"2016","key":"10.1016\/j.vph.2022.106977_bb0080","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"2020","key":"10.1016\/j.vph.2022.106977_bb0085","first-page":"111","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2022.106977_bb0090","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2009-05-222380","article-title":"Altered fibrin clot structure\/function in patients with idiopathic venous thromboembolism and in their relatives","volume":"114","author":"Undas","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.vph.2022.106977_bb0095","doi-asserted-by":"crossref","first-page":"III39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation."},{"key":"10.1016\/j.vph.2022.106977_bb0100","doi-asserted-by":"crossref","first-page":"804","DOI":"10.33963\/KP.a2021.0010","article-title":"Endothelial function in patients with critical and non-critical limb ischemia undergoing endovascular treatment","volume":"79","author":"Kaczmarczyk","year":"2021","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.vph.2022.106977_bb0105","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1046\/j.1538-7836.2003.00301.x","article-title":"Increased plasma fibrin gel porosity in patients with type I diabetes during continuous subcutaneous insulin infusion","volume":"1","author":"J\u00f6rneskog","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2022.106977_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2019.103487","article-title":"Plasma fibrin clot proteomics in healthy subjects: relation to clot permeability and lysis time","volume":"208","author":"Z\u0105bczyk","year":"2019","journal-title":"J. Proteome"},{"key":"10.1016\/j.vph.2022.106977_bb0115","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jvs.2008.07.010","article-title":"Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication","volume":"48","author":"Bhasin","year":"2008","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.vph.2022.106977_bb0120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0049-3848(94)90245-3","article-title":"Fibrinogen structure, activation, polymerization and fibrin gel structure","volume":"75","author":"Blomb\u00e4ck","year":"1994","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2022.106977_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041966","article-title":"Identification of fibrin clot-bound plasma proteins","volume":"7","author":"Talens","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2022.106977_bb0130","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2022.106977_bb0135","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.12223","article-title":"Statin therapy and levels of hemostatic factors in a healthy population: the multi-ethnic study of atherosclerosis","volume":"11","author":"Adams","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2022.106977_bb0140","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0167-5273(00)00439-3","article-title":"Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia","volume":"77","author":"Musial","year":"2001","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2022.106977_bb0145","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0021-9258(17)43435-1","article-title":"Binding of fibronectin by the acute phase reactant C-reactive protein","volume":"259","author":"Salonen","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2022.106977_bb0150","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1160\/TH09-02-0118","article-title":"Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease: beneficial effects of simvastatin treatment","volume":"102","author":"Undas","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2022.106977_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2020.10.014","article-title":"Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects","volume":"197","author":"Siudut","year":"2021","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2022.106977_bb0160","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.thromres.2013.09.017","article-title":"Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin","volume":"133","author":"Kov\u00e1cs","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2022.106977_bb0165","first-page":"627","article-title":"Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia","volume":"98","author":"Guven","year":"2006","journal-title":"J. Natl. Med. Assoc."},{"key":"10.1016\/j.vph.2022.106977_bb0170","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.16648","article-title":"Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial","volume":"190","author":"Schol-Gelok","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.vph.2022.106977_bb0175","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.clinthera.2021.03.011","article-title":"Effect of statin therapy on the carboxypeptidase U (CPU, TAFIa, CPB2) system in patients with hyperlipidemia: a proof-of-concept observational study","volume":"43","author":"Claesen","year":"2021","journal-title":"Clin. Ther."},{"key":"10.1016\/j.vph.2022.106977_bb0180","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.metabol.2010.08.013","article-title":"Up-regulation of hepatic low-density lipoprotein receptor\u2013related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl\u2013coenzyme a reductase inhibitor","volume":"60","author":"Moon","year":"2011","journal-title":"Metabolism."},{"key":"10.1016\/j.vph.2022.106977_bb0185","doi-asserted-by":"crossref","first-page":"13045","DOI":"10.1073\/pnas.0806312105","article-title":"Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.vph.2022.106977_bb0190","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FJC.0b013e31821e8cb2","article-title":"Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events","volume":"58","author":"Undas","year":"2011","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.vph.2022.106977_bb0195","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.120.046397","article-title":"The effect of PCSK9 (Proprotein convertase Subtilisin\/Kexin type 9) inhibition on the risk of venous thromboembolism","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.vph.2022.106977_bb0200","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.phrs.2015.12.001","article-title":"Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: a systematic review and meta-analysis","volume":"103","author":"Sahebkar","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.vph.2022.106977_bb0205","doi-asserted-by":"crossref","DOI":"10.4172\/2161-0509.S6-001","article-title":"Statins therapy: effects on plasma fibrinogen levels and fibrinolysis","volume":"03","author":"Cappelletti","year":"2013","journal-title":"J. Nutr. Disord. Ther."},{"key":"10.1016\/j.vph.2022.106977_bb0210","first-page":"673","article-title":"Changes over time in the prevention of recurrent coronary artery disease in everyday practice","volume":"131","author":"P\u0119ksa","year":"2021","journal-title":"Pol. Arch. Intern. Med."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912200026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912200026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:21:17Z","timestamp":1761528077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153718912200026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":42,"alternative-id":["S153718912200026X"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2022.106977","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2022.106977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106977"}}